Your reference journal for coronary, valvular and structural interventions

issue

Dec 20, 2019

Volume 15 Number 12

This issue looks at MR severity as a predictor of therapeutic benefit in TMVI using the Tendyne system; the impact of elevated tricuspid valve inflow gradients after TTVR; TAVI vs SAVR in low surgical risk patients; the ANGIOLITE trial, a first-in-man comparison of the Angiolite SES with an EES in CAD; and an examination of stent thrombosis after endovascular revascularisation of the superficial femoral artery.

Editorial

The role of the Heart Team in the planning of aortic valve replacement

Costa G, Fukutomi M, Søndergaard L

10.4244/EIJV15I12A191

free

GLOBAL LEADERS: looking now at the bigger picture

Guedeney P, Montalescot G

10.4244/EIJV15I12A192

free

Predicting TMVR outcomes – the Tendyne experience

Piazza N, Overtchouk P, Ben-Shoshan J

10.4244/EIJV15I12A193

free

What constitutes sufficient clinical evidence for stents? SpotLITE on the evaluation of novel coronary devices

Sanchez J, Stefanini G, Byrne RA

10.4244/EIJV15I12A194

free

Transtricuspid gradient after percutaneous edge-to-edge tricuspid valve repair: are we looking at the right side?

Gavazzoni M, Taramasso M

10.4244/EIJV15I12A195

free

Perspectives

Spotlight on N-STEMI ACS: getting the right patients the right treatment, and at the right time

Kite T, Gersh BJ, Gershlick A

10.4244/EIJV15I12A196

free

Interventions for valvular disease and heart failure

Meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients at low surgical risk

Witberg G, Landes U, Lador A, Yahav D, Kornowski R

10.4244/EIJ-D-19-00663

free

Clinical impact of elevated tricuspid valve inflow gradients after transcatheter edge-to-edge tricuspid valve repair

Orban M, Orban M, Braun D, Deseive S, Kupka D, Stocker TJ, Bagaev E, Karam N, Hagl C, Massberg S, Näbauer M, Hausleiter J

10.4244/EIJ-D-19-00237

free

Mitral regurgitation severity predicts one-year therapeutic benefit of Tendyne transcatheter mitral valve implantation

Badhwar V, Sorajja P, Duncan A, Thourani V, Schaefer U, Grayburn P, Dumonteil N, Babaliaros V, Garatti A, Lessick J, Chuang M, Blanke P, Muller DW

10.4244/EIJ-D-19-00333

free

Will the Evolut Low Risk trial change my practice?

O'Sullivan C, Reardon MJ, Søndergaard L, Treede H, Jüni P, Windecker S

10.4244/EIJ-D-19-00587

free

Will the PARTNER 3 Low Risk Trial change my practice?

McConkey H, Modine T, Latib A, Jüni P, Windecker S, Leon MB

10.4244/EIJ-D-19-00847

free

Coronary interventions

First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial

Moreu J, Moreno-Gómez R, Perez de Prado A, García del Blanco B, Trillo R, Pinar E, Molina E, Zueco J, Merchán A, Díaz-Fernández J, Amat-Santos I

10.4244/EIJ-D-19-00206

free

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

Serruys PW, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen J, Rademaker-Havinga T, Garg S, Steg G, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F

10.4244/EIJ-D-19-00202

free

Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial

Kuroda K, Otake H, Shinohara M, Kuroda M, Tsuda S, Toba T, Nagano Y, Toh R, Ishida T, Shinke T, Hirata K

10.4244/EIJ-D-18-01073

free

Peripheral interventions

Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery

Bradaric C, Koppara T, Müller A, Haller B, Ott I, Cassese S, Fusaro M, Kastrati A, Laugwitz K, Ibrahim T

10.4244/EIJ-D-19-00187

free